株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

インスリンデリバリー:医療機器のパイプライン評価

Insulin Delivery - Medical Devices Pipeline Assessment, 2018

発行 GlobalData 商品コード 635168
出版日 ページ情報 英文 446 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.53円で換算しております。
Back to Top
インスリンデリバリー:医療機器のパイプライン評価 Insulin Delivery - Medical Devices Pipeline Assessment, 2018
出版日: 2018年05月01日 ページ情報: 英文 446 Pages
概要

当レポートでは、世界のインスリンデリバリー装置の市場における、主要なパイプライン製品とその治験の進行状況について調査すると共に、製品特性の比較分析 (治験の進行段階別) や、主要企業のプロファイルおよび代表的製品、昨今の市場動静 (資本取引・事業提携など) といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 イントロダクション

  • インスリンデリバリーの概要

第3章 現在治験中の製品

  • パイプライン製品:治験段階別
  • パイプライン製品:分野別
  • パイプライン製品:領域別
  • パイプライン製品:規制経路別
  • パイプライン製品:推定認証時期別
  • 現在進行中の治験

第4章 インスリンデリバリー:各企業で治験中のパイプライン製品

  • インスリンデリバリーの企業:治験段階別のパイプライン製品
  • インスリンデリバリー:治験段階別のパイプライン製品

第5章 インスリンデリバリーの企業・製品の概要

  • Amrita Vishwa Vidyapeetham
  • Andain, Inc
  • Asti Corporation
  • Becton Dickinson and Co
  • Bigfoot Biomedical Inc
  • Calibra Medical, Inc.
  • Cam Med LLC
  • Cambridge Consultants Ltd
  • Capillary Biomedical, Inc.
  • Cellnovo Ltd Company Overview
  • Dance Biopharm Inc Company Overview
  • Debiotech SA
  • Defymed SAS
  • Dermisonics Inc (Inactive)
  • Eli Lilly and Co
  • Emperra GmbH E-Health Technologies
  • Flinders University of SA
  • Hospira Inc
  • Imagine Medical Device Inc.
  • InsuLenz
  • Insulet Corp
  • InsuLine Medical Ltd
  • Iowa State University
  • LifeScan Inc
  • Medical International Technologies (Mit Canada) Inc
  • MedPro Safety Products, Inc.
  • MedSolve Technologies, Inc.
  • Medtronic plc
  • MicroPort Scientific Corp
  • NanoDerma Ltd
  • 日東電工
  • North Carolina State University
  • Novo Nordisk AS
  • Phluid Corporation
  • Phosphagenics Ltd
  • Prometheon Pharma LLC
  • Roche Diabetes Care Inc
  • Sanofi
  • Sensile Medical AG
  • SFC Fluidics LLC
  • Spring Health Solutions Ltd.
  • Tandem Diabetes Care Inc
  • Transdermal Specialties, Inc.
  • University of KwaZulu-Natal
  • University of Missouri-Kansas City
  • University of North Carolina
  • University of Toronto
  • Univlabs Technologies Pvt Ltd
  • Valeritas Inc
  • ViCentra BV
  • Vigmed Holding AB
  • WaveForm Technologies Inc
  • Ypsomed Holding AG
  • Zealand Pharma AS

第6章 インスリンデリバリー市場:昨今の動向 (全86件)

第7章 付録

図表

List of Tables

  • Table 1: Insulin Delivery - Pipeline Products by Stage of Development
  • Table 2: Insulin Delivery - Pipeline Products by Segment
  • Table 3: Insulin Delivery - Pipeline Products by Territory
  • Table 4: Insulin Delivery - Pipeline Products by Regulatory Path
  • Table 5: Insulin Delivery - Pipeline Products by Estimated Approval Date
  • Table 6: Insulin Delivery - Ongoing Clinical Trials
  • Table 7: Insulin Delivery Companies - Pipeline Products by Stage of Development
  • Table 8: Insulin Delivery - Pipeline Products by Stage of Development
  • Table 9: Amrita Vishwa Vidyapeetham Pipeline Products & Ongoing Clinical Trials Overview
  • Table 10: Amrita Insulin Pump - Product Status
  • Table 11: Amrita Insulin Pump - Product Description
  • Table 12: Andain, Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 13: Gaia Med Diamond Semi-Disposable Pump - Product Status
  • Table 14: Gaia Med Diamond Semi-Disposable Pump - Product Description
  • Table 15: Gemini Pump - Product Status
  • Table 16: Gemini Pump - Product Description
  • Table 17: Asti Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 18: Medical Microneedle System - Product Status
  • Table 19: Medical Microneedle System - Product Description
  • Table 20: Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview
  • Table 21: BD FlowSmart Infusion Set - Product Status
  • Table 22: BD FlowSmart Infusion Set - Product Description
  • Table 23: Extended Wear Insulin Infusion Set - Product Status
  • Table 24: Extended Wear Insulin Infusion Set - Product Description
  • Table 25: Bigfoot Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 26: Injection Based Insulin Delivery System - Product Status
  • Table 27: Injection Based Insulin Delivery System - Product Description
  • Table 28: Calibra Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 29: OneTouch Via - Product Status
  • Table 30: OneTouch Via - Product Description
  • Table 31: Cam Med LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 32: Evopump - Product Status
  • Table 33: Evopump - Product Description
  • Table 34: Cambridge Consultants Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 35: KiCoPen - Product Status
  • Table 36: KiCoPen - Product Description
  • Table 37: Capillary Biomedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 38: CSII Catheter - Product Status
  • Table 39: CSII Catheter - Product Description
  • Table 40: Capillary Biomedical, Inc. - Ongoing Clinical Trials Overview
  • Table 41: CSII Catheter - A Pilot Study for the Systematic Evaluation of the Inflammatory Response to Commercially Available Insulin Infusion Catheters in Subcutaneous Adipose Tissue
  • Table 42: Cellnovo Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 43: Cellnovo Wireless Insulin Pump System - Product Status
  • Table 44: Cellnovo Wireless Insulin Pump System - Product Description
  • Table 45: Wireless Insulin Pump System Integrated With inControl AP - Product Status
  • Table 46: Wireless Insulin Pump System Integrated With inControl AP - Product Description
  • Table 47: Dance Biopharm Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 48: Dance-501 - Product Status
  • Table 49: Dance-501 - Product Description
  • Table 50: Debiotech SA Pipeline Products & Ongoing Clinical Trials Overview
  • Table 51: Jewel Pump - Product Status
  • Table 52: Jewel Pump - Product Description
  • Table 53: JewelPUMP2 - Product Status
  • Table 54: JewelPUMP2 - Product Description
  • Table 55: Defymed SAS Pipeline Products & Ongoing Clinical Trials Overview
  • Table 56: ExOlin - Product Status
  • Table 57: ExOlin - Product Description
  • Table 58: Dermisonics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Table 59: U-Strip - Product Status
  • Table 60: U-Strip - Product Description
  • Table 61: Eli Lilly and Co Pipeline Products & Ongoing Clinical Trials Overview
  • Table 62: AID System - Product Status
  • Table 63: AID System - Product Description
  • Table 64: AIR Insulin System - Product Status
  • Table 65: AIR Insulin System - Product Description
  • Table 66: Humalog Junior KwikPen - Product Status
  • Table 67: Humalog Junior KwikPen - Product Description
  • Table 68: Integrated Insulin Management System - Product Status
  • Table 69: Integrated Insulin Management System - Product Description
  • Table 70: Emperra GmbH E-Health Technologies Pipeline Products & Ongoing Clinical Trials Overview
  • Table 71: ESYSTA BT Pen - Product Status
  • Table 72: ESYSTA BT Pen - Product Description
  • Table 73: Flinders University of SA Pipeline Products & Ongoing Clinical Trials Overview
  • Table 74: Re-Timer - Product Status
  • Table 75: Re-Timer - Product Description
  • Table 76: Hospira Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 77: Integrated Symbiq/EndoTool System - Product Status
  • Table 78: Integrated Symbiq/EndoTool System - Product Description
  • Table 79: Imagine Medical Device Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 80: Insulin Syringe - Product Status
  • Table 81: Insulin Syringe - Product Description
  • Table 82: InsuLenz Pipeline Products & Ongoing Clinical Trials Overview
  • Table 83: Smart Polymer Contact Lens - Product Status
  • Table 84: Smart Polymer Contact Lens - Product Description
  • Table 85: Insulet Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 86: OmniPod - Humalog U200 - Product Status
  • Table 87: OmniPod - Humalog U200 - Product Description
  • Table 88: OmniPod - New Version - Product Status
  • Table 89: OmniPod - New Version - Product Description
  • Table 90: Omnipod Dash Insulin Management System - Product Status
  • Table 91: Omnipod Dash Insulin Management System - Product Description
  • Table 92: Insulet Corp - Ongoing Clinical Trials Overview
  • Table 93: Omnipod Dash Insulin Management System - Evaluating Glucose Control in Patients with Type 1 Diabetes Under Free-living Conditions with the Insulet Automated Glucose Control System: IDE3
  • Table 94: InsuLine Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 95: InsuPad - Product Status
  • Table 96: InsuPad - Product Description
  • Table 97: Long Acting Insulin Therapy Device - Product Status
  • Table 98: Long Acting Insulin Therapy Device - Product Description
  • Table 99: Iowa State University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 100: Feed Forward Insulin Delivery System - Product Status
  • Table 101: Feed Forward Insulin Delivery System - Product Description
  • Table 102: LifeScan Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 103: ONETOUCH Ping Verio Insulin Pump With Meter Remote - Product Status
  • Table 104: ONETOUCH Ping Verio Insulin Pump With Meter Remote - Product Description
  • Table 105: Medical International Technologies (Mit Canada) Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 106: Med-Jet MIT-P-I - Product Status
  • Table 107: Med-Jet MIT-P-I - Product Description
  • Table 108: MedPro Safety Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 109: Insulin Guard Self-Injector Safety Needle - Product Status
  • Table 110: Insulin Guard Self-Injector Safety Needle - Product Description
  • Table 111: MedSolve Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 112: Freehand Patch Pump - Product Status
  • Table 113: Freehand Patch Pump - Product Description
  • Table 114: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 115: MiniMed Mio Advance Infusion Set - Product Status
  • Table 116: MiniMed Mio Advance Infusion Set - Product Description
  • Table 117: MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 118: Angel Touch - Product Status
  • Table 119: Angel Touch - Product Description
  • Table 120: La Fenice Pen - Product Status
  • Table 121: La Fenice Pen - Product Description
  • Table 122: La Fenice V - Product Status
  • Table 123: La Fenice V - Product Description
  • Table 124: NanoDerma Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 125: Intranasal Insulin Delivery Device - Product Status
  • Table 126: Intranasal Insulin Delivery Device - Product Description
  • Table 127: Nitto Denko Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 128: PassPort Transdermal Basal Insulin Patch - 12 Hours - Product Status
  • Table 129: PassPort Transdermal Basal Insulin Patch - 12 Hours - Product Description
  • Table 130: PassPort Transdermal Basal Insulin Patch - 24Hours - Product Status
  • Table 131: PassPort Transdermal Basal Insulin Patch - 24Hours - Product Description
  • Table 132: North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 133: Pulsatile Noninvasive Drug Delivery System - Product Status
  • Table 134: Pulsatile Noninvasive Drug Delivery System - Product Description
  • Table 135: Novo Nordisk AS Pipeline Products & Ongoing Clinical Trials Overview
  • Table 136: AERx iDMS - Product Status
  • Table 137: AERx iDMS - Product Description
  • Table 138: Phluid Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 139: Ambulatory Diabetes Pump - Product Status
  • Table 140: Ambulatory Diabetes Pump - Product Description
  • Table 141: Phosphagenics Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 142: TPM-Insulin Patch - Product Status
  • Table 143: TPM-Insulin Patch - Product Description
  • Table 144: Prometheon Pharma LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 145: TruePatch - Basal Insulin - Product Status
  • Table 146: TruePatch - Basal Insulin - Product Description
  • Table 147: TruePatch - Rapid-Acting (Bolus) Insulin - Product Status
  • Table 148: TruePatch - Rapid-Acting (Bolus) Insulin - Product Description
  • Table 149: Roche Diabetes Care Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 150: Solo MicroPump Insulin Delivery System - Product Status
  • Table 151: Solo MicroPump Insulin Delivery System - Product Description
  • Table 152: Roche Diabetes Care Inc - Ongoing Clinical Trials Overview
  • Table 153: Solo MicroPump Insulin Delivery System - Patient-reported Outcomes with the Accu-Chek Solo Micropump System vs. Multiple Daily Injection Therapy Versus Mylife OmniPod in People with Type I Diabetes
  • Table 154: Sanofi Pipeline Products & Ongoing Clinical Trials Overview
  • Table 155: Fix-Flex Device - Product Status
  • Table 156: Fix-Flex Device - Product Description
  • Table 157: Toujeo Max SoloStar - Product Status
  • Table 158: Toujeo Max SoloStar - Product Description
  • Table 159: Sensile Medical AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 160: Bolus Patch - Product Status
  • Table 161: Bolus Patch - Product Description
  • Table 162: SFC Fluidics LLC Pipeline Products & Ongoing Clinical Trials Overview

List of Figures

  • Figure 1: Insulin Delivery - Pipeline Products by Stage of Development
  • Figure 2: Insulin Delivery - Pipeline Products by Segment
  • Figure 3: Insulin Delivery - Pipeline Products by Territory
  • Figure 4: Insulin Delivery - Pipeline Products by Regulatory Path
  • Figure 5: Insulin Delivery - Pipeline Products by Estimated Approval Date
  • Figure 6: Insulin Delivery - Ongoing Clinical Trials
目次
Product Code: GDME0543EPD

GlobalData's Medical Devices sector report, "Insulin Delivery - Medical Devices Pipeline Assessment, 2018" provides an overview of Insulin Delivery currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Insulin Delivery pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope:

  • Extensive coverage of the Insulin Delivery under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Insulin Delivery and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.

Reasons to buy:

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Insulin Delivery under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Insulin Delivery Overview

3. Products under Development

  • 3.1. Insulin Delivery - Pipeline Products by Stage of Development
  • 3.2. Insulin Delivery - Pipeline Products by Segment
  • 3.3. Insulin Delivery - Pipeline Products by Territory
  • 3.4. Insulin Delivery - Pipeline Products by Regulatory Path
  • 3.5. Insulin Delivery - Pipeline Products by Estimated Approval Date
  • 3.6. Insulin Delivery - Ongoing Clinical Trials

4. Insulin Delivery - Pipeline Products under Development by Companies

  • 4.1. Insulin Delivery Companies - Pipeline Products by Stage of Development
  • 4.2. Insulin Delivery - Pipeline Products by Stage of Development

5. Insulin Delivery Companies and Product Overview

  • 5.1. Amrita Vishwa Vidyapeetham Company Overview
  • 5.2. Andain, Inc Company Overview
  • 5.3. Asti Corporation Company Overview
  • 5.4. Becton Dickinson and Co Company Overview
  • 5.5. Bigfoot Biomedical Inc Company Overview
  • 5.6. Calibra Medical, Inc. Company Overview
  • 5.7. Cam Med LLC Company Overview
  • 5.8. Cambridge Consultants Ltd Company Overview
  • 5.9. Capillary Biomedical, Inc. Company Overview
  • 5.10. Cellnovo Ltd Company Overview
  • 5.11. Dance Biopharm Inc Company Overview
  • 5.12. Debiotech SA Company Overview
  • 5.13. Defymed SAS Company Overview
  • 5.14. Dermisonics Inc (Inactive) Company Overview
  • 5.15. Eli Lilly and Co Company Overview
  • 5.16. Emperra GmbH E-Health Technologies Company Overview
  • 5.17. Flinders University of SA Company Overview
  • 5.18. Hospira Inc Company Overview
  • 5.19. Imagine Medical Device Inc. Company Overview
  • 5.20. InsuLenz Company Overview
  • 5.21. Insulet Corp Company Overview
  • 5.22. InsuLine Medical Ltd Company Overview
  • 5.23. Iowa State University Company Overview
  • 5.24. LifeScan Inc Company Overview
  • 5.25. Medical International Technologies (Mit Canada) Inc Company Overview
  • 5.26. MedPro Safety Products, Inc. Company Overview
  • 5.27. MedSolve Technologies, Inc. Company Overview
  • 5.28. Medtronic plc Company Overview
  • 5.29. MicroPort Scientific Corp Company Overview
  • 5.30. NanoDerma Ltd Company Overview
  • 5.31. Nitto Denko Corp Company Overview
  • 5.32. North Carolina State University Company Overview
  • 5.33. Novo Nordisk AS Company Overview
  • 5.34. Phluid Corporation Company Overview
  • 5.35. Phosphagenics Ltd Company Overview
  • 5.36. Prometheon Pharma LLC Company Overview
  • 5.37. Roche Diabetes Care Inc Company Overview
  • 5.38. Sanofi Company Overview
  • 5.39. Sensile Medical AG Company Overview
  • 5.40. SFC Fluidics LLC Company Overview
  • 5.41. Spring Health Solutions Ltd. Company Overview
  • 5.42. Tandem Diabetes Care Inc Company Overview
  • 5.43. Transdermal Specialties, Inc. Company Overview
  • 5.44. University of KwaZulu-Natal Company Overview
  • 5.45. University of Missouri-Kansas City Company Overview
  • 5.46. University of North Carolina Company Overview
  • 5.47. University of Toronto Company Overview
  • 5.48. Univlabs Technologies Pvt Ltd Company Overview
  • 5.49. Valeritas Inc Company Overview
  • 5.50. ViCentra BV Company Overview
  • 5.51. Vigmed Holding AB Company Overview
  • 5.52. WaveForm Technologies Inc Company Overview
  • 5.53. Ypsomed Holding AG Company Overview
  • 5.54. Zealand Pharma AS Company Overview

6. Insulin Delivery- Recent Developments

  • 6.1. Apr 23, 2018: Tandem Diabetes Care Announces Agreements for Distribution of Insulin Pump Products in Australia and New Zealand
  • 6.2. Apr 18, 2018: Abbott Reports First-Quarter 2018 Results
  • 6.3. Apr 17, 2018: Valeritas Announces V-Go Distribution Agreement in Australia and New Zealand
  • 6.4. Apr 17, 2018: Johnson and Johnson Reports 2018 First-Quarter Results
  • 6.5. Apr 17, 2018: Johnson & Johnson Reports 2018 First-Quarter Results
  • 6.6. Apr 12, 2018: Inolife R&D Signs LOI With ADW Diabetes to Make Its Inojex Needle-Free Injector Available to Diabetics in USA
  • 6.7. Apr 11, 2018: Zealand and Roche Diabetes Care enter Phase 3 study collaboration for treatment of congenital hyperinsulinism with dasiglucagon
  • 6.8. Apr 10, 2018: Pfizer Signs Lease for The Spiral at Hudson Yards in Manhattan
  • 6.9. Apr 10, 2018: Tandem Diabetes Care Announces Preliminary First Quarter 2018 Results
  • 6.10. Apr 09, 2018: Tandem Diabetes Care and Movi SpA Announce Agreement for Distribution of Insulin Pump Products in Italy
  • 6.11. Apr 05, 2018: New Sanofi insulin savings program aims to lower out-of-pocket costs for people living with diabetes
  • 6.12. Apr 05, 2018: AstraZeneca: Non-Executive Directors' Retirement Plans
  • 6.13. Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics
  • 6.14. Apr 02, 2018: Retractable Technologies Reports Results for the Year 2017
  • 6.15. Mar 28, 2018: Sanofi: Pre - quarterly Results Communication
  • 6.16. Mar 28, 2018: MicroPort Scientific Announces 2017 Annual Results
  • 6.17. Mar 27, 2018: Ypsomed Expands to North America
  • 6.18. Mar 27, 2018: FDA approves Toujeo Max SoloStar
  • 6.19. Mar 27, 2018: MicroPort Scientific Announces Year Ended 31 December 2017 Financial Results
  • 6.20. Mar 26, 2018: FDA Approves Inclusion of Data on Cardiovascular Outcomes and Severe Hypoglycaemia in the Tresiba Label
  • 6.21. Mar 23, 2018: Colour change for insulin injection Fiasp to avoid mix ups with Tresiba
  • 6.22. Mar 23, 2018: Aradigm Reports Fourth Quarter 2017 And Full Year Financial Results
  • 6.23. Mar 23, 2018: 2017 fiscal year: B. Braun increases sales and earnings, with investments of one billion euros
  • 6.24. Mar 20, 2018: Zealand Pharma''s first Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia successfully meets its primary objective
  • 6.25. Mar 20, 2018: Dominic J. Caruso to Retire as Chief Financial Officer of Johnson & Johnson
  • 6.26. Mar 15, 2018: Midatech announces changes in Senior Management Team
  • 6.27. Mar 13, 2018: MannKind Announces STAT Study Results Accepted for Presentation at American Diabetes Association's 78th Scientific Sessions
  • 6.28. Mar 09, 2018: Maura Dickler, M.D. To Become Vice President Of Late Phase Development At Lilly Oncology
  • 6.29. Mar 08, 2018: Changes to the Roche Enlarged Corporate Executive Committee
  • 6.30. Mar 06, 2018: Sanofi's Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director
  • 6.31. Mar 06, 2018: Raumedic reorganizes its management
  • 6.32. Mar 05, 2018: Henry Ford Health System Appoints Adnan Munkarah As New Executive Vice President & Chief Clinical Officer
  • 6.33. Mar 05, 2018: Pfizer Names Dan R. Littman As Board Director
  • 6.34. Mar 02, 2018: Lexmark Healthcare to Showcase New Solutions to Paper-Based Problems at HIMSS18
  • 6.35. Mar 01, 2018: Tandem Diabetes Care Announces 2017 Financial Results
  • 6.36. Mar 01, 2018: Nektar Therapeutics Announces Fourth Quarter And Year-End 2017 Financial Results
  • 6.37. Mar 01, 2018: Poly Medicure: Commencement of Commercial Production
  • 6.38. Feb 27, 2018: MannKind Reports 2017 Fourth Quarter and Full Year Financial Results
  • 6.39. Feb 23, 2018: Pfizer Appoints Albert Bourla As Board Director
  • 6.40. Feb 22, 2018: Tempus Launches Tempus xE, Whole Exome Sequencing To Empower Data-Driven Cancer Care and Research
  • 6.41. Feb 22, 2018: Integer Holdings Reports Results for Fourth Quarter and Full Year 2017
  • 6.42. Feb 22, 2018: Integer Announces Strategy Focused on Portfolio Management and Operational Excellence; Aligns Senior Management to Execute Strategic Imperatives
  • 6.43. Feb 21, 2018: Medtronic Introduces MiniMed Mio Advance Infusion Set for People with Diabetes
  • 6.44. Feb 21, 2018: Zealand Pharma reports completion of the first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia
  • 6.45. Feb 21, 2018: Insulet Reports Fourth Quarter Revenue of $130.5 Million In Fourth Quarter Of 2017
  • 6.46. Feb 15, 2018: Reduced Time in Hypoglycemia Demonstrated in Tandem Diabetes Care's Pivotal Trial for the t:slim X2 Insulin Pump with Predictive Low Glucose Suspend Feature; Data to be Presented at ATTD 2018 Conference
  • 6.47. Feb 15, 2018: Tandem Diabetes Care and Rubin Medical Announce Agreement for Distribution of Insulin Pump Products in Scandinavia
  • 6.48. Feb 15, 2018: ConvaTec Group Annual Results 2017
  • 6.49. Feb 15, 2018: ConvaTec Group Reports Annual Financial Results For 2017
  • 6.50. Feb 14, 2018: Toujeo reduced risk of severe low blood sugar compared to insulin glargine 100 Units/mL and insulin detemir
  • 6.51. Feb 13, 2018: Four start-ups chosen for the B. Braun Accelerator Program
  • 6.52. Feb 12, 2018: Innovative Medical Devices for the Treatment of Diabetes, Defymed Strengthens Its Position as a Worldwide Leader
  • 6.53. Feb 12, 2018: Integer Elects James Hinrichs to its Board of Directors
  • 6.54. Feb 09, 2018: Aradigm Announces Personnel Changes
  • 6.55. Feb 08, 2018: MicroPort Signs Strategic Agreement with Neptunus Biotechnology
  • 6.56. Feb 07, 2018: Sanofi Delivers 2017 Business EPS in line with Guidance
  • 6.57. Feb 07, 2018: Stevanato Group introduces its new brand identity at Pharmapack - Paris, the key international Pharmaceutical Packaging and Drug Delivery event
  • 6.58. Feb 06, 2018: BD Announces Results For 2018 First Fiscal Quarter; Provides Fiscal 2018 Guidance Updated For Inclusion Of Bard
  • 6.59. Feb 06, 2018: MannKind Names David Kendall As Chief Medical Officer
  • 6.60. Feb 06, 2018: Raumedic modernizing German headquarters
  • 6.61. Feb 05, 2018: JDRF and Cam Med Partner to Develop Flexible Patch Pump for Automated Insulin Delivery Systems
  • 6.62. Feb 05, 2018: Defymed at ATTD Conference
  • 6.63. Feb 02, 2018: AstraZeneca: Full-Year 2017 Results
  • 6.64. Feb 01, 2018: Roche reports good results in 2017
  • 6.65. Feb 01, 2018: Novo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies)
  • 6.66. Jan 31, 2018: Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance
  • 6.67. Jan 30, 2018: Pfizer Reports Fourth-Quarter And Full-Year 2017 Results
  • 6.68. Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region
  • 6.69. Jan 29, 2018: Aerogen Officially Opens Middle East Office
  • 6.70. Jan 27, 2018: Prometheon Pharma Completes Pilot Study of Insulin Patch in Mini-Pigs
  • 6.71. Jan 24, 2018: Abbott Reports Fourth-Quarter 2017 Results
  • 6.72. Jan 23, 2018: Johnson & Johnson Reports 2017 Fourth-Quarter Results
  • 6.73. Jan 19, 2018: Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee
  • 6.74. Jan 17, 2018: Valeritas Announces its V-Go Wearable Insulin Delivery Device is now available in Puerto Rico
  • 6.75. Jan 16, 2018: OrthoXel Announce FDA 510k and CE Mark Approval for their Orthopaedic Trauma Product the Apex Tibial Nail System
  • 6.76. Jan 09, 2018: MicroPort Selected as "2017 China Innovative Medical Device Company"
  • 6.77. Jan 09, 2018: MicroPort Awarded 2017 Shanghai Pilot Enterprise with Outstanding Innovation
  • 6.78. Jan 09, 2018: JDRF Research Accomplishments Lead the Way to Prevent Future Type 1 Diabetes Diagnoses
  • 6.79. Jan 09, 2018: Valeritas Appoints Joseph Saldanha as Chief Business Officer
  • 6.80. Jan 09, 2018: Tandem Diabetes Care Announces Preliminary 2017 Results and Provides 2018 Guidance
  • 6.81. Jan 08, 2018: Tandem Diabetes Care Reports Successful Completion of First Pilot Study Using t:slim X2 Insulin Pump with TypeZero Hybrid Closed Loop Technology and Dexcom G6 Integration; Confirms IDCL Multi-site Study Timeline
  • 6.82. Jan 08, 2018: MicroPort Lifesciences Displayed La Fenice Insulin Pump at CDS2017
  • 6.83. Jan 08, 2018: Medicare Part D (Prescription Drug) Plans May Now Cover Omnipod
  • 6.84. Jan 03, 2018: Tandem Diabetes Care Commences Full Manufacturing Operations at New San Diego Facility
  • 6.85. Jan 02, 2018: Midatech enters into a Loan Agreement with MidCap Financial
  • 6.86. Jan 02, 2018: Integer Names Kirk Thor Chief Human Resources Officer

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer
Back to Top